Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rush Street Interactive, Inc.RSI · Entity 2291 | Director | March 14, 2026 | March 17, 2026 |
| ZEVRA THERAPEUTICS, INC.KMPH · Entity 5212 | 10% owner | October 05, 2018 | October 09, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rush Street Interactive, Inc.
Report date March 14, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 20,789 |
Reported balance
After 2026-03-14 transaction · row 1
1 source rowRow 1 · 2026-03-14 · Grant · Acquired 7,968 · Balance 20,789 F1: On March 14, 2026, the Reporting Person was awarded 7,968 restricted stock units (the "RSUs") under the Rush Street Interactive, Inc. 2020 Omnibus Equity Incentive Plan, as amended. The RSUs vest as of the Issuer's next annual meeting of stockholders to be held in calendar year 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 14, 2026, the Reporting Person was awarded 7,968 restricted stock units (the "RSUs") under the Rush Street Interactive, Inc. 2020 Omnibus Equity Incentive Plan, as amended. The RSUs vest as of the Issuer's next annual meeting of stockholders to be held in calendar year 2027.
ZEVRA THERAPEUTICS, INC.
Report date October 05, 2018 · Filed October 09, 2018
Jointly reported with Delaware Street Capital Master Fund, L.P., DSC Advisors, L.P., DSC Managers, L.L.C., DSC Advisors, L.L.C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 4,095,914 |
Reported balance
After 2018-10-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-10-05 · Purchase · Acquired 2,000,000 · Balance 4,095,914 F1: The filing of this Form 4 shall not be construed as an admission that DSC Advisors, L.P. ("DSCA), the investment manager of Delaware Street Master Fund, L.P. (the "Fund"), DSC Managers, L.L.C. ("DSCM"), the general partner of the Fund, DSC Advisors, L.L.C. ("DSCA LLC"), the general partner of DSCA, or Andrew G. Bluhm, the principal of DSCA LLC, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the Common Stock, par value $0.0001 (the "Common Stock"), of KemPharm, Inc. (the "Issuer") purchased by the Fund. Pursuant to Rule 16a-1, each of DSCA, DSCM, DSCA LLC and Mr. Bluhm disclaim such beneficial ownership. F2: The Fund holds the shares of Common Stock directly. DSCA serves as the investment manager to the Fund. DSCA LLC serves as the general partner of DSCA. DSCM receives a portion of the profits in the form of a capital allocation from, and owns a partnership interest in, the Fund. Andrew G. Bluhm reports the Common Stock held directly by the Fund because, as the principal of DSCA LLC at the time of purchase, he controlled the disposition and voting of the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The filing of this Form 4 shall not be construed as an admission that DSC Advisors, L.P. ("DSCA), the investment manager of Delaware Street Master Fund, L.P. (the "Fund"), DSC Managers, L.L.C. ("DSCM"), the general partner of the Fund, DSC Advisors, L.L.C. ("DSCA LLC"), the general partner of DSCA, or Andrew G. Bluhm, the principal of DSCA LLC, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the Common Stock, par value $0.0001 (the "Common Stock"), of KemPharm, Inc. (the "Issuer") purchased by the Fund. Pursuant to Rule 16a-1, each of DSCA, DSCM, DSCA LLC and Mr. Bluhm disclaim such beneficial ownership.
F2: The Fund holds the shares of Common Stock directly. DSCA serves as the investment manager to the Fund. DSCA LLC serves as the general partner of DSCA. DSCM receives a portion of the profits in the form of a capital allocation from, and owns a partnership interest in, the Fund. Andrew G. Bluhm reports the Common Stock held directly by the Fund because, as the principal of DSCA LLC at the time of purchase, he controlled the disposition and voting of the securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2026 Filed Mar 17, 2026 18:24 UTC | Rush Street Interactive, Inc. RSI · Entity 2291 | GrantClass A Common Stock | 7,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001083033-26-000002 · wk-form4_1773786274.xml · nonDerivative · entry 1 BLUHM ANDREW G · CIK 0001083033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,789 F1 · acquired: On March 14, 2026, the Reporting Person was awarded 7,968 restricted stock units (the "RSUs") under the Rush Street Interactive, Inc. 2020 Omnibus Equity Incentive Plan, as amended. The RSUs vest as of the Issuer's next annual meeting of stockholders to be held in calendar year 2027. Read SEC document |
| May 29, 2025 Filed May 29, 2025 17:54 UTC | Rush Street Interactive, Inc. RSI · Entity 2291 | GrantClass A Common Stock | 10,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001793659-25-000126 · wk-form4_1748555661.xml · nonDerivative · entry 1 BLUHM ANDREW G · CIK 0001083033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,821 F1 · acquired: On May 29, 2025, the Reporting Person was awarded 10,958 restricted stock units (the "RSUs") under the Rush Street Interactive, Inc. 2020 Omnibus Equity Incentive Plan, as amended. The RSUs vest as of the Issuer's next annual meeting of stockholders to be held in calendar year 2026. Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 17:56 UTC | Rush Street Interactive, Inc. RSI · Entity 2291 | GrantClass A Common Stock | 1,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001793659-25-000076 · wk-form4_1742507768.xml · nonDerivative · entry 1 BLUHM ANDREW G · CIK 0001083033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,863 F1 · price: On March 19, 2025, the Reporting Person was awarded 1,863 restricted stock units (the "RSUs") under the Rush Street Interactive, Inc. 2020 Omnibus Equity Incentive Plan, as amended. The RSUs vest as of the Issuer's next annual meeting of stockholders to be held in calendar year 2026. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 16:01 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock, par value $0.0001 | 2,000,000 | $3.00 | $6,000,000.00 |
DisclosureSEC source: 0000899243-18-026415 · doc4.xml · nonDerivative · entry 1 Delaware Street Capital Master Fund, L.P. · CIK 0001648576 · 10% owner DSC Advisors, L.P. · CIK 0001299434 · 10% owner DSC Managers, L.L.C. · CIK 0001648612 · 10% owner DSC Advisors, L.L.C. · CIK 0001648574 · 10% owner BLUHM ANDREW G · CIK 0001083033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,095,914 F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that DSC Advisors, L.P. ("DSCA), the investment manager of Delaware Street Master Fund, L.P. (the "Fund"), DSC Managers, L.L.C. ("DSCM"), the general partner of the Fund, DSC Advisors, L.L.C. ("DSCA LLC"), the general partner of DSCA, or Andrew G. Bluhm, the principal of DSCA LLC, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the Common Stock, par value $0.0001 (the "Common Stock"), of KemPharm, Inc. (the "Issuer") purchased by the Fund. Pursuant to Rule 16a-1, each of DSCA, DSCM, DSCA LLC and Mr. Bluhm disclaim such beneficial ownership. F2 · ownership.direct: The Fund holds the shares of Common Stock directly. DSCA serves as the investment manager to the Fund. DSCA LLC serves as the general partner of DSCA. DSCM receives a portion of the profits in the form of a capital allocation from, and owns a partnership interest in, the Fund. Andrew G. Bluhm reports the Common Stock held directly by the Fund because, as the principal of DSCA LLC at the time of purchase, he controlled the disposition and voting of the securities. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:05 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock, par value $0.0001 | 304,283 | $4.00 | $1,217,132.00 |
DisclosureSEC source: 0000899243-18-020957 · doc4.xml · nonDerivative · entry 1 Delaware Street Capital Master Fund, L.P. · CIK 0001648576 · 10% owner DSC Advisors, L.P. · CIK 0001299434 · 10% owner DSC Managers, L.L.C. · CIK 0001648612 · 10% owner DSC Advisors, L.L.C. · CIK 0001648574 · 10% owner BLUHM ANDREW G · CIK 0001083033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,095,914 F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that DSC Advisors, L.P. ("DSCA), the investment manager of Delaware Street Master Fund, L.P. (the "Fund"), DSC Managers, L.L.C. ("DSCM"), the general partner of the Fund, DSC Advisors, L.L.C. ("DSCA LLC"), the general partner of DSCA, or Andrew G. Bluhm, the principal of DSCA LLC, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the Common Stock, par value $0.0001 (the "Common Stock"), of KemPharm, Inc. (the "Issuer") purchased by the Fund. Pursuant to Rule 16a-1, each of DSCA, DSCM, DSCA LLC and Mr. Bluhm disclaim such beneficial ownership. F2 · ownership.direct: The Fund holds the shares of Common Stock directly. DSCA serves as the investment manager to the Fund. DSCA LLC serves as the general partner of DSCA. DSCM receives a portion of the profits in the form of a capital allocation from, and owns a partnership interest in, the Fund. Andrew G. Bluhm reports the Common Stock held directly by the Fund because, as the principal of DSCA LLC at the time of purchase, he controlled the disposition and voting of the securities. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 13:30 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock, par value $0.0001 | 138,857 | $3.30 | $458,603.01 |
DisclosureSEC source: 0000899243-17-022122 · doc4.xml · nonDerivative · entry 3 Delaware Street Capital Master Fund, L.P. · CIK 0001648576 · 10% owner DSC Advisors, L.P. · CIK 0001299434 · 10% owner DSC Managers, L.L.C. · CIK 0001648612 · 10% owner DSC Advisors, L.L.C. · CIK 0001648574 · 10% owner BLUHM ANDREW G · CIK 0001083033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791,631 F4 · price: The purchase price represents a weighted average of the purchase price for multiple transactions on the same trading day. The range of purchase prices was $3.25 to $3.35. The Reporting Persons will provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that DSC Advisors, L.P. ("DSCA), the investment manager of Delaware Street Master Fund, L.P. (the "Fund"), DSC Managers, L.L.C. ("DSCM"), the general partner of the Fund, DSC Advisors, L.L.C. ("DSCA LLC"), the general partner of DSCA, or Andrew G. Bluhm, the principal of DSCA LLC, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the Common Stock, par value $0.0001 (the "Common Stock"), of KemPharm, Inc. (the "Issuer") purchased by the Fund. Pursuant to Rule 16a-1, each of DSCA, DSCM, DSCA LLC and Mr. Bluhm disclaim such beneficial ownership. F2 · ownership.direct: The Fund holds the shares of Common Stock directly. DSCA serves as the investment manager to the Fund. DSCA LLC serves as the general partner of DSCA. DSCM receives a portion of the profits in the form of a capital allocation from, and owns a partnership interest in, the Fund. Andrew G. Bluhm reports the Common Stock held directly by the Fund because, as the principal of DSCA LLC at the time of purchase, he controlled the disposition and voting of the securities. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 13:30 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock, par value $0.0001 | 200 | $3.25 | $650.00 |
DisclosureSEC source: 0000899243-17-022122 · doc4.xml · nonDerivative · entry 2 Delaware Street Capital Master Fund, L.P. · CIK 0001648576 · 10% owner DSC Advisors, L.P. · CIK 0001299434 · 10% owner DSC Managers, L.L.C. · CIK 0001648612 · 10% owner DSC Advisors, L.L.C. · CIK 0001648574 · 10% owner BLUHM ANDREW G · CIK 0001083033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,652,774 F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that DSC Advisors, L.P. ("DSCA), the investment manager of Delaware Street Master Fund, L.P. (the "Fund"), DSC Managers, L.L.C. ("DSCM"), the general partner of the Fund, DSC Advisors, L.L.C. ("DSCA LLC"), the general partner of DSCA, or Andrew G. Bluhm, the principal of DSCA LLC, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the Common Stock, par value $0.0001 (the "Common Stock"), of KemPharm, Inc. (the "Issuer") purchased by the Fund. Pursuant to Rule 16a-1, each of DSCA, DSCM, DSCA LLC and Mr. Bluhm disclaim such beneficial ownership. F2 · ownership.direct: The Fund holds the shares of Common Stock directly. DSCA serves as the investment manager to the Fund. DSCA LLC serves as the general partner of DSCA. DSCM receives a portion of the profits in the form of a capital allocation from, and owns a partnership interest in, the Fund. Andrew G. Bluhm reports the Common Stock held directly by the Fund because, as the principal of DSCA LLC at the time of purchase, he controlled the disposition and voting of the securities. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 13:30 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock, par value $0.0001 | 186,831 | $3.25 | $607,574.41 |
DisclosureSEC source: 0000899243-17-022122 · doc4.xml · nonDerivative · entry 1 Delaware Street Capital Master Fund, L.P. · CIK 0001648576 · 10% owner DSC Advisors, L.P. · CIK 0001299434 · 10% owner DSC Managers, L.L.C. · CIK 0001648612 · 10% owner DSC Advisors, L.L.C. · CIK 0001648574 · 10% owner BLUHM ANDREW G · CIK 0001083033 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,652,574 F3 · price: The purchase price represents a weighted average of the purchase price for multiple transactions on the same trading day. The range of purchase prices was $3.15 to $3.30. The Reporting Persons will provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F1 · balance_after: The filing of this Form 4 shall not be construed as an admission that DSC Advisors, L.P. ("DSCA), the investment manager of Delaware Street Master Fund, L.P. (the "Fund"), DSC Managers, L.L.C. ("DSCM"), the general partner of the Fund, DSC Advisors, L.L.C. ("DSCA LLC"), the general partner of DSCA, or Andrew G. Bluhm, the principal of DSCA LLC, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the Common Stock, par value $0.0001 (the "Common Stock"), of KemPharm, Inc. (the "Issuer") purchased by the Fund. Pursuant to Rule 16a-1, each of DSCA, DSCM, DSCA LLC and Mr. Bluhm disclaim such beneficial ownership. F2 · ownership.direct: The Fund holds the shares of Common Stock directly. DSCA serves as the investment manager to the Fund. DSCA LLC serves as the general partner of DSCA. DSCM receives a portion of the profits in the form of a capital allocation from, and owns a partnership interest in, the Fund. Andrew G. Bluhm reports the Common Stock held directly by the Fund because, as the principal of DSCA LLC at the time of purchase, he controlled the disposition and voting of the securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.